AstraZeneca rises as key lung cancer drug scores another win
AstraZeneca rises as key lung cancer drug scores another win
Tagrisso from AstraZeneca has shown positive results in a trial for advanced non-small cell lung cancer patients with a specific genetic mutation. It slowed disease progression and could be the first targeted treatment option for stage 3 patients. AstraZeneca said the trial showed a statistically significant and highly clinically meaningful improvement in progression-free survival for patients whose cancer was unable to be removed by surgery and had responded to initial chemoradiation.
Tagrisso from AstraZeneca has shown positive results in a trial for advanced non-small cell lung cancer patients with a specific genetic mutation. It slowed disease progression and could be the first targeted treatment option for stage 3 patients. AstraZeneca said the trial showed a statistically significant and highly clinically meaningful improvement in progression-free survival for patients whose cancer was unable to be removed by surgery and had responded to initial chemoradiation.
We use cookies to improve your experience on our site and to show you relevant advertising. To find out more, read our updated privacy policy and cookie policy
Through RSS Feeds 
Tagrisso from AstraZeneca has shown positive results in a trial for advanced non-small cell lung cancer patients with a specific genetic mutation. It slowed disease progression and could be the first targeted treatment option for stage 3 patients. AstraZeneca said the trial showed a statistically significant and highly clinically meaningful improvement in progression-free survival for patients whose cancer was unable to be removed by surgery and had responded to initial chemoradiation. 
